

# Luca Magnani

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2012514/publications.pdf>

Version: 2024-02-01

61  
papers

3,036  
citations

147801

31  
h-index

168389

53  
g-index

67  
all docs

67  
docs citations

67  
times ranked

6038  
citing authors

#	ARTICLE	IF	CITATIONS
1	Photobiomodulation Therapy: A New Light in the Treatment of Systemic Sclerosis Skin Ulcers. <i>Rheumatology and Therapy</i> , 2022, 9, 891-905.	2.3	8
2	Management of Systemic Sclerosis Patients in the COVID-19 Era: The Experience of an Expert Specialist Reference Center. <i>Clinical Medicine Insights: Circulatory, Respiratory and Pulmonary Medicine</i> , 2021, 15, 117954842110013.	0.9	4
3	Long-term methotrexate use in rheumatoid arthritis patients: real-world data from the MARTE study. <i>Minerva Medica</i> , 2021, 112, 246-254.	0.9	2
4	The many faces of cancer evolution. <i>IScience</i> , 2021, 24, 102403.	4.1	15
5	Clinical and Pathological Features of Breast Cancer in Systemic Sclerosis: Results from the Sclero-Breast Study. <i>Journal of Personalized Medicine</i> , 2021, 11, 580.	2.5	4
6	Clinicopathological Bird's-Eye View of Left Atrial Myocardial Fibrosis in 121 Patients With Persistent Atrial Fibrillation. <i>Circulation: Arrhythmia and Electrophysiology</i> , 2020, 13, e007588.	4.8	9
7	Mapping the breast cancer metastatic cascade onto ctDNA using genetic and epigenetic clonal tracking. <i>Nature Communications</i> , 2020, 11, 1446.	12.8	28
8	Single-cell transcriptomics reveals multi-step adaptations to endocrine therapy. <i>Nature Communications</i> , 2019, 10, 3840.	12.8	93
9	SREBP1 drives Keratin-80-dependent cytoskeletal changes and invasive behavior in endocrine-resistant ER <sup>+</sup> breast cancer. <i>Nature Communications</i> , 2019, 10, 2115.	12.8	42
10	FOXM1 modulates 5-FU resistance in colorectal cancer through regulating TYMS expression. <i>Scientific Reports</i> , 2019, 9, 1505.	3.3	96
11	Dickkopf-3 links HSF1 and YAP/TAZ signalling to control aggressive behaviours in cancer-associated fibroblasts. <i>Nature Communications</i> , 2019, 10, 130.	12.8	116
12	Extensive and systematic rewiring of histone post-translational modifications in cancer model systems. <i>Nucleic Acids Research</i> , 2018, 46, 3817-3832.	14.5	31
13	Chromatin Immunoprecipitation and High-Throughput Sequencing (ChIP-Seq): Tips and Tricks Regarding the Laboratory Protocol and Initial Downstream Data Analysis. <i>Methods in Molecular Biology</i> , 2018, 1767, 271-288.	0.9	2
14	Enhancer mapping uncovers phenotypic heterogeneity and evolution in patients with luminal breast cancer. <i>Nature Medicine</i> , 2018, 24, 1469-1480.	30.7	98
15	TGF- $\beta$ 2 induces miR-100 and miR-125b but blocks let-7a through LIN28B controlling PDAC progression. <i>Nature Communications</i> , 2018, 9, 1845.	12.8	101
16	Acquired CYP19A1 amplification is an early specific mechanism of aromatase inhibitor resistance in ER <sup>+</sup> metastatic breast cancer. <i>Nature Genetics</i> , 2017, 49, 444-450.	21.4	77
17	Fundamental Pathways in Breast Cancer 3: Estrogen Biology. , 2017, , 19-26.		0
18	Histone Posttranslational Modifications in Breast Cancer and Their Use in Clinical Diagnosis and Prognosis. , 2016, , 467-477.		0

#	ARTICLE	IF	CITATIONS
19	Molecular Insights of Pathways Resulting from Two Common PIK3CA Mutations in Breast Cancer. <i>Cancer Research</i> , 2016, 76, 3989-4001.	0.9	27
20	Guidelines for the selection of functional assays to evaluate the hallmarks of cancer. <i>Biochimica Et Biophysica Acta: Reviews on Cancer</i> , 2016, 1866, 300-319.	7.4	89
21	Expression of CDK7, Cyclin H, and MAT1 Is Elevated in Breast Cancer and Is Prognostic in Estrogen Receptor-Positive Breast Cancer. <i>Clinical Cancer Research</i> , 2016, 22, 5929-5938.	7.0	66
22	Going off the grid: ER± breast cancer beyond estradiol. <i>Journal of Molecular Endocrinology</i> , 2016, 57, F1-F5.	2.5	2
23	Spearhead Nanometric Field-Effect Transistor Sensors for Single-Cell Analysis. <i>ACS Nano</i> , 2016, 10, 3214-3221.	14.6	95
24	ChIP-BIT: Bayesian inference of target genes using a novel joint probabilistic model of ChIP-seq profiles. <i>Nucleic Acids Research</i> , 2016, 44, e65-e65.	14.5	15
25	Stem Cells in Translational Cancer Research. <i>Stem Cells International</i> , 2015, 2015, 1-2.	2.5	0
26	LMTK3 Represses Tumor Suppressor-like Genes through Chromatin Remodeling in Breast Cancer. <i>Cell Reports</i> , 2015, 12, 837-849.	6.4	21
27	APOBEC3B-Mediated Cytidine Deamination Is Required for Estrogen Receptor Action in Breast Cancer. <i>Cell Reports</i> , 2015, 13, 108-121.	6.4	105
28	Differential epigenetic reprogramming in response to specific endocrine therapies promotes cholesterol biosynthesis and cellular invasion. <i>Nature Communications</i> , 2015, 6, 10044.	12.8	108
29	DMXL2 drives epithelial to mesenchymal transition in hormonal therapy resistant breast cancer through notch hyper-activation. <i>Oncotarget</i> , 2015, 6, 22467-22479.	1.8	33
30	The pioneer factor PBX1 is a novel driver of metastatic progression in ER±-positive breast cancer. <i>Oncotarget</i> , 2015, 6, 21878-21891.	1.8	45
31	Nuclear receptors and chromatin: an inducible couple. <i>Journal of Molecular Endocrinology</i> , 2014, 52, R137-R149.	2.5	36
32	The transcriptional co-repressor TLE3 suppresses basal signaling on a subset of estrogen receptor ± target genes. <i>Nucleic Acids Research</i> , 2014, 42, 11339-11348.	14.5	26
33	Nicastrin and Notch4 drive endocrine therapy resistance and epithelial to mesenchymal transition in MCF7 breast cancer cells. <i>Breast Cancer Research</i> , 2014, 16, R62.	5.0	66
34	LRH-1 Governs Vital Transcriptional Programs in Endocrine-Sensitive and -Resistant Breast Cancer Cells. <i>Cancer Research</i> , 2014, 74, 2015-2025.	0.9	48
35	Poised epigenetic states and acquired drug resistance in cancer. <i>Nature Reviews Cancer</i> , 2014, 14, 747-753.	28.4	252
36	Chromatin and epigenetic determinants of estrogen receptor alpha (ESR1) signaling. <i>Molecular and Cellular Endocrinology</i> , 2014, 382, 633-641.	3.2	53

#	ARTICLE	IF	CITATIONS
37	Brief Report: Interleukin-6 as an Inflammatory Mediator and Target of Therapy in Chronic Periaortitis. Arthritis and Rheumatism, 2013, 65, 2469-2475.	6.7	51
38	Leg Ulcers Associated With Giant Cell Arteritis Relapse. International Journal of Lower Extremity Wounds, 2013, 12, 69-70.	1.1	1
39	Genome-wide reprogramming of the chromatin landscape underlies endocrine therapy resistance in breast cancer. Proceedings of the National Academy of Sciences of the United States of America, 2013, 110, E1490-9.	7.1	149
40	KPNA7, an oocyte- and embryo-specific karyopherin- $\beta$ subtype, is required for porcine embryo development. Reproduction, Fertility and Development, 2012, 24, 382.	0.4	35
41	Tocilizumab: a novel therapy for patients with large-vessel vasculitis. Rheumatology, 2012, 51, 151-156.	1.9	203
42	ChIPing away at breast cancer. Lancet Oncology, The, 2012, 13, 1185-1187.	10.7	5
43	Chromatin landscape and endocrine response in breast cancer. Epigenomics, 2012, 4, 675-683.	2.1	14
44	Small-vessel vasculitis surrounding an uninfamed temporal artery and isolated vasa vasorum vasculitis of the temporal artery: Two subsets of giant cell arteritis. Arthritis and Rheumatism, 2012, 64, 549-556.	6.7	69
45	Identification of PBX1 Target Genes in Cancer Cells by Global Mapping of PBX1 Binding Sites. PLoS ONE, 2012, 7, e36054.	2.5	40
46	Pioneer factors: directing transcriptional regulators within the chromatin environment. Trends in Genetics, 2011, 27, 465-474.	6.7	138
47	New indications for biological therapies. Internal and Emergency Medicine, 2011, 6, 1-9.	2.0	7
48	PBX1 Genomic Pioneer Function Drives ER $\alpha$ Signaling Underlying Progression in Breast Cancer. PLoS Genetics, 2011, 7, e1002368.	3.5	167
49	Global H3K9 dimethylation status is not affected by transcription, translation, or DNA replication in porcine zygotes. Molecular Reproduction and Development, 2010, 77, 420-429.	2.0	10
50	Brg1 Is Required for Cdx2-Mediated Repression of Oct4 Expression in Mouse Blastocysts. PLoS ONE, 2010, 5, e10622.	2.5	53
51	Manipulation of SMARCA2 and SMARCA4 transcript levels in porcine embryos differentially alters development and expression of SMARCA1, SOX2, NANOG, and EIF1. Reproduction, 2009, 137, 23-33.	2.6	21
52	Gene expression and development of early pig embryos produced by serial nuclear transfer. Molecular Reproduction and Development, 2009, 76, 555-563.	2.0	19
53	Differential remodeling of mono- and trimethylated H3K27 during porcine embryo development. Molecular Reproduction and Development, 2009, 76, 1033-1042.	2.0	43
54	Developmental capacity of porcine nuclear transfer embryos correlate with levels of chromatin remodeling transcripts in donor cells. Molecular Reproduction and Development, 2008, 75, 766-776.	2.0	7

#	ARTICLE	IF	CITATIONS
55	In vitro and in vivo derived porcine embryos possess similar, but not identical, patterns of Oct4, Nanog, and Sox2 mRNA expression during cleavage development. <i>Molecular Reproduction and Development</i> , 2008, 75, 1726-1735.	2.0	52
56	Expression of eukaryotic elongation initiation factor 1A differentially marks zygotic genome activation in biparental and parthenogenetic porcine embryos and correlates with in vitro developmental potential. <i>Reproduction, Fertility and Development</i> , 2008, 20, 818.	0.4	23
57	Developmental arrest induced in cleavage stage porcine embryos following microinjection of mRNA encoding Brahma (Smarca 2), a chromatin remodeling protein. <i>Molecular Reproduction and Development</i> , 2007, 74, 1262-1267.	2.0	11
58	GMTR: Two-dimensional geo-fit multitarget retrieval model for Michelson Interferometer for Passive Atmospheric Sounding/Environmental Satellite observations. <i>Applied Optics</i> , 2006, 45, 716.	2.1	67
59	MIPAS-ENVISAT limb-sounding measurements: trade-off study for improvement of horizontal resolution. <i>Applied Optics</i> , 2004, 43, 5814.	2.1	19
60	Level 2 near-real-time analysis of MIPAS measurements on ENVISAT. , 2003, , .		4
61	Geo-fit approach to the analysis of limb-scanning satellite measurements. , 2002, 4539, 369.		0